

TO THE NATIONAL SECURITIES MARKET COMMISSION

For the purposes set forth in Article 227 of Law 6/2023, of March 17, on Securities Markets and Investment Services, and related provisions, Faes Farma, S.A. hereby informs the market of the following

OTHER RELEVANT INFORMATION**A) EXTRAORDINARY SHAREHOLDERS' MEETING RESOLUTION**

At the Extraordinary General Shareholders' Meeting of the Company validly held today on second call, the proposals of the Board of Directors included in the sole item on the Agenda were approved:

- **Approval of the acquisition of 100% of the share capital of Sifi, S.P.A.**

With this approval by the shareholders, we are taking another step towards completing the acquisition of Sifi, which represents a transformational step in our ambition and strategy for 2030, strengthening our position in ophthalmology, a therapeutic area with significant growth potential, and accelerating our international expansion.

July 16th, 2025